Mankind Pharma Limited

BSE: MANKIND543904ISIN INE634S01028

Healthcare
Pharmaceuticals
BSE 200

Share price

₹2,533.15+56.05 (+2.26%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,640.30
52W low: ₹1,909.90
Off 52W high: -4.06%
1M return: +2.15%
3M return: +3.31%
6M return: +7.25%
1Y return: +6.91%
20D avg volume: 69,698
50 DMA: ₹2,387.20
200 DMA: ₹2,317.13

Key ratios Consolidated

Market cap: ₹1,04,631 Cr
Current price: ₹2,533.15
52W high / low: ₹2,640.30 / ₹1,909.90
Face value: ₹1.00
P/E: 46.22
P/B: 5.95
EPS (TTM): ₹54.80
Book value / share: ₹425.72
ROE: —
ROCE: 13.70%
Operating margin: —
Net margin: —
Debt / equity: 0.38
Net debt: ₹5,920 Cr
Interest cover: 4.63
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 64.7 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	4,338	4,031	3,443	3,567	3,697	3,570	3,079	3,230	3,077	2,893	2,441	2,607
	94.85	45.00	114.29	72.75	91.87	79.88	251.33	77.32	109.43	100.60	92.13	70.13
	4,433	4,076	3,557	3,640	3,789	3,650	3,331	3,307	3,186	2,994	2,533	2,677
	3,507	3,310	2,878	3,028	3,167	3,113	2,818	2,813	2,339	2,330	1,964	2,119
	674.81	684.85	554.95	553.04	594.36	585.68	554.25	536.11	461.99	472.98	436.34	456.74
	547.73	547.28	498.36	411.67	412.97	404.97	411.12	387.30	424.28	432.99	342.29	352.79
	948.94	913.50	751.60	823.71	825.18	783.41	715.80	709.71	646.43	633.78	581.51	568.35
	104.94	109.98	141.75	157.20	169.68	170.65	190.54	220.93	7.10	10.91	9.38	9.19
	235.73	225.70	223.08	222.60	221.82	218.68	230.87	192.30	105.62	107.74	104.69	109.73
	1,013	962.63	803.08	846.07	888.48	886.58	805.00	755.27	705.15	765.35	531.20	604.51
	925.43	765.51	679.34	612.38	621.70	537.32	513.11	493.89	846.75	663.71	569.16	557.73
	0.00	0.00	-23.16	-106.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	925.43	765.51	656.18	505.79	621.70	537.32	513.11	493.89	846.75	663.71	569.16	557.73
	212.99	195.36	99.75	95.12	103.84	95.87	86.44	112.81	190.44	124.55	94.98	102.52
	716.12	574.09	559.42	413.88	520.18	444.62	424.65	384.52	658.88	543.07	476.59	459.81
	17.23	13.76	13.44	9.90	12.39	10.62	10.30	9.45	16.31	13.39	11.76	11.33
Key metrics
	1,266	1,101	1,021	885.59	1,013	926.65	934.52	907.12	959.47	782.36	683.23	676.65
	29.20%	27.30%	29.70%	24.80%	27.40%	26.00%	30.30%	28.10%	31.20%	27.00%	28.00%	26.00%
	16.50%	14.20%	16.20%	11.60%	14.10%	12.50%	13.80%	11.90%	21.40%	18.80%	19.50%	17.60%
	4.50%	—	3.70%	—	3.60%	—	3.20%	—	—	—	—	—
	17.30%	12.90%	11.80%	10.40%	20.20%	23.40%	26.10%	23.90%	—	—	—	—
	37.70%	29.10%	31.70%	7.60%	-21.10%	-18.10%	-10.90%	-16.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	15,379	14,278	12,207	10,335	8,749
	326.89	358.79	536.79	280.86	128.57
	15,705	14,636	12,744	10,616	8,878
	12,723	12,186	10,240	8,231	7,219
	2,468	2,288	2,016	1,854	1,814
	2,005	1,728	1,656	1,410	809.24
	3,438	3,184	2,692	2,275	1,918
	513.87	639.28	429.41	33.53	44.47
	907.11	886.18	621.22	398.25	325.92
	3,625	3,424	3,008	2,315	2,017
	2,983	2,451	2,504	2,384	1,659
	-129.75	-129.75	0.00	0.00	0.00
	2,853	2,321	2,504	2,384	1,659
	603.22	394.58	509.74	457.59	361.56
	2,264	1,938	2,011	1,942	1,310
	54.33	46.35	49.28	47.75	32.00
Key metrics
	4,274	3,846	3,555	2,816	2,029
	27.79%	26.90%	29.10%	27.20%	23.20%
	14.72%	13.60%	16.50%	18.80%	15.00%
	—	13.70%	13.30%	—	—
	13.27%	17.00%	18.10%	18.10%	—
	27.60%	-3.60%	3.60%	48.30%	—
	—	2,495	1,953	—	—
	—	1.61	1.20	—	—
	—	0.38	0.58	—	—
	—	5,920	8,104	—	—
	—	64.7	74.7	—	—
Balance sheet
	—	28,080	27,760	—	—
	—	7,140	7,175	—	—
	—	391.69	407.36	—	—
	—	1,730	1,538	—	—
	—	2,144	2,094	—	—
	—	805.25	802.82	—	—
	—	2,960	2,908	—	—
	—	1,341	1,133	—	—
	—	6,507	5,664	—	—
	—	6,312	8,511	—	—
	—	3,419	2,971	—	—
	—	2,893	5,540	—	—
	—	16,561	14,568	—	—
Cash flow
	—	3,121	2,413	—	—
	—	-196.42	-12,683	—	—
	—	-2,953	10,290	—	—
	—	625.96	460.79	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	3,145	2,964	2,582	2,633	2,609	2,541	2,127	2,397	2,530	2,403	2,153	2,359
	58.83	33.96	126.70	56.52	77.67	64.22	219.32	69.82	105.76	94.83	83.85	67.23
	3,204	2,998	2,709	2,689	2,686	2,606	2,346	2,466	2,636	2,498	2,237	2,426
	2,420	2,241	1,898	2,100	2,162	2,112	1,917	1,942	1,865	1,921	1,692	1,849
	246.45	257.42	203.58	201.14	230.46	224.76	216.76	179.72	182.12	204.24	213.15	205.21
	566.31	560.44	419.66	452.66	432.84	414.47	384.25	445.60	484.31	503.96	477.13	500.36
	718.46	683.56	550.85	617.33	600.29	584.87	536.75	521.79	525.86	522.10	507.93	492.68
	87.74	94.95	125.28	138.37	147.20	146.70	162.25	199.47	1.92	6.26	4.03	4.26
	120.19	111.02	109.43	107.69	99.03	96.93	105.24	87.03	85.42	83.40	82.29	89.73
	678.12	624.67	538.87	575.16	604.54	613.78	555.44	474.45	548.48	622.47	474.47	533.07
	783.59	756.57	810.83	588.71	524.63	493.66	428.75	524.25	770.45	577.37	544.86	576.35
	0.00	0.00	-22.82	-83.42	0.00	0.00	0.00	—	—	—	—	—
	783.59	756.57	788.01	505.29	524.63	493.66	428.75	524.25	770.45	577.37	544.86	576.35
	201.64	198.08	74.40	55.82	65.73	80.90	46.29	107.87	168.01	93.12	90.69	89.28
	581.95	558.49	713.61	449.47	458.90	412.76	382.46	416.38	634.43	513.49	454.17	487.07
	14.09	13.53	17.29	10.89	11.12	10.00	18.54	10.35	15.04	12.09	11.34	12.16
Key metrics
	991.52	962.54	1,023	751.35	770.86	737.29	696.24	810.75	857.79	667.03	631.18	670.34
	31.50%	32.50%	39.60%	28.50%	29.50%	29.00%	32.70%	33.80%	33.90%	27.80%	29.30%	28.40%
	18.50%	18.80%	27.60%	17.10%	17.60%	16.20%	18.00%	17.40%	25.10%	21.40%	21.10%	20.70%
	4.20%	—	4.80%	—	3.50%	—	3.00%	—	—	—	—	—
	20.60%	16.60%	21.40%	9.90%	3.10%	5.70%	-1.20%	1.60%	—	—	—	—
	26.80%	35.30%	86.60%	7.90%	-27.70%	-19.60%	-15.80%	-14.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23
Income statement
	11,324	10,421	9,498	9,265	8,127
	276.01	326.10	493.21	266.64	162.78
	11,600	10,747	9,991	9,531	8,290
	8,660	8,326	7,685	7,272	6,727
	908.59	860.52	800.43	861.74	711.05
	1,999	1,729	1,810	2,072	1,866
	2,570	2,367	2,132	1,982	1,701
	446.34	562.21	371.76	14.57	27.75
	448.33	428.57	378.01	317.61	269.58
	2,417	2,343	2,207	2,049	1,884
	2,940	2,421	2,306	2,260	1,563
	-106.24	-106.24	0.00	—	—
	2,833	2,315	2,306	2,260	1,563
	529.94	277.44	421.74	436.16	314.58
	2,304	2,038	1,945	1,823	1,248
	55.80	49.37	94.80	45.52	31.16
Key metrics
	3,728	3,306	3,056	2,592	1,860
	32.92%	31.70%	32.20%	28.00%	22.90%
	20.34%	19.60%	20.50%	19.70%	15.40%
	—	15.00%	13.60%	—	—
	17.06%	9.70%	2.50%	14.00%	—
	37.89%	4.70%	6.70%	46.10%	—
	—	2,415	2,024	—	—
	—	1.35	1.19	—	—
	—	0.34	0.50	—	—
	—	5,483	7,054	—	—
	—	55.0	54.6	—	—
Balance sheet
	—	24,625	23,828	—	—
	—	4,288	4,794	—	—
	—	87.66	200.29	—	—
	—	1,164	894.67	—	—
	—	1,088	1,091	—	—
	—	537.62	601.17	—	—
	—	1,939	1,941	—	—
	—	681.25	563.62	—	—
	—	5,473	4,092	—	—
	—	5,571	7,254	—	—
	—	3,042	2,308	—	—
	—	2,529	4,946	—	—
	—	16,397	14,640	—	—
Cash flow
	—	2,752	2,322	—	—
	—	-387.96	-12,115	—	—
	—	-2,477	9,783	—	—
	—	337.16	298.43	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +8.64%
Sales CAGR 5Y: —
Profit CAGR 3Y: +17.74%
Profit CAGR 5Y: —
Sales YoY (TTM): +17.06%
Profit YoY (TTM): +37.89%

Consolidated

Sales CAGR 3Y: +17.73%
Sales CAGR 5Y: —
Profit CAGR 3Y: +13.96%
Profit CAGR 5Y: —
Sales YoY (TTM): +13.27%
Profit YoY (TTM): +27.60%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.61%

Quarter	September 2026	June 2026
Promoter %	72.61%	72.61%

Holder	Type	Holding	Previous	Change
Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee)	Promoter	20.18%	20.18%	0.00%
Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee)	Promoter	19.35%	19.35%	0.00%
Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee)	Promoter	14.95%	14.95%	0.00%
SHEETAL ARORA	Promoter	4.67%	4.67%	0.00%
PUJA JUNEJA	Promoter Group	2.79%	2.79%	0.00%
NPS TRUST- A/C LIC PENSION FUND SCHEME - STATE GOV	Public	2.65%	—	—
POONAM JUNEJA	Promoter Group	2.56%	2.56%	0.00%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA RET	Public	2.45%	—	—
ARJUN JUNEJA	Promoter Group	1.97%	1.97%	0.00%
RAMESH JUNEJA	Promoter	1.66%	1.66%	0.00%
RAJEEV JUNEJA	Promoter	1.57%	1.57%	0.00%
SBI ESG EXCLUSIONARY STRATEGY FUND	Public	1.49%	—	—
ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S	Public	1.21%	—	—
GOVERNMENT PENSION FUND GLOBAL	Public	1.06%	1.29%	-0.23%
EKLAVYA JUNEJA	Promoter Group	0.94%	0.94%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Intimation of participation in the Investor Conference.3 Nov 2026 · Company Update / Analyst / Investor Meet
Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY2730 Oct 2026 · Company Update / Earnings Call Transcript
Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL29 Oct 2026 · Company Update / Credit Rating
In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet27 Oct 2026 · Company Update / Investor Presentation
Newspaper Advertisment - Unaudited Fianncial Results of the Company for Q2 & H1 FY2727 Oct 2026 · Company Update / Newspaper Publication
Please find attached link for audio recording of the Investor Conference Call held on October 26, 202626 Oct 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on Financial Results of the Company for Q2 & H1FY2726 Oct 2026 · Company Update / Investor Presentation
Press release on financial results Q2&H1FY2726 Oct 2026 · Company Update / Press Release / Media Release
Scheme of arrangement for amalgamation of Prolijune Lifescinces Private Limited (WOS) with Mankind Pharma Limited26 Oct 2026 · Company Update / Scheme of Arrangement
Scheme of arrangement for amalgamation of Pavi Buildwell Private Limited (WOS) with Mankind Pharma Limited26 Oct 2026 · Company Update / Scheme of Arrangement
Assets cover certificate for the quarter and half year ended 30th September 202626 Oct 2026 · Others / Reg. 54 - Asset Cover details
Outcome of Board Meeting26 Oct 2026 · Board Meeting / Outcome of Board Meeting
Results for the Quarter and Half year ended 30th September 2026.26 Oct 2026 · Result / Financial Results
Due to a technical issue, the meeting link provided in the earlier intimation regarding "Rescheduling of the Earnings Conference Call for Q2 & H1 FY27", uploaded today at 15:39:16 IST, ....22 Oct 2026 · Company Update / Analyst / Investor Meet
Please find attached Intimation regarding Schedule of Analyst/ Institutional Investors Meet22 Oct 2026 · Company Update / Analyst / Investor Meet
Please find attached intimation regarding rescheduling of Earnings Conference Call for Q2 & H1 FY2722 Oct 2026 · Company Update / Analyst / Investor Meet
Intimation regarding payment of interest and redemption of Non-Convertible Debentures ("NCD")16 Oct 2026 · Others / Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD
Please find attached intimation regarding ESG Rating15 Oct 2026 · Company Update / General
Please find attached press release titled "Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies".15 Oct 2026 · Company Update / Press Release / Media Release
Please find attached intimation regarding investment by the Company.15 Oct 2026 · Company Update / Acquisition
Please find attached outcome of Board Meeting held on October 15, 2026.15 Oct 2026 · Others / Outcome without intimation
Please find attached intimation regarding Earnings Conference Call for Q2 & H1 FY27.12 Oct 2026 · Company Update / Analyst / Investor Meet
Please find attached certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended on September 30, 2026.9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited standalon and ....8 Oct 2026 · Board Meeting / Board Meeting
Please find attached intimation regarding resignation of Statutory Auditors of the Bharat Serums and Vaccines Limited, a matterial wholly owned subsidiary company.28 Sep 2026 · Company Update / General
Please find attached, the intimation of clsoure of the trading window.25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report17 Sep 2026 · AGM/EGM / Postal Ballot
Please find attached Voting Results of Postal Ballot and Scrutinizer''s Report17 Sep 2026 · AGM/EGM / Postal Ballot
Please find attached intimation regarding ESG Rating15 Sep 2026 · Company Update / General
Please find attached intimation of participation in the Investor Conferences11 Sep 2026 · Company Update / Analyst / Investor Meet
Please find attached update on voluntary liquidation of Bharat Serums and Vaccines Limited, a wholly owned subsidiary company.7 Sep 2026 · Company Update / General
Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP Plan1 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Please find attached final update on sale of stake of Broadway Hospitality Services Private Limited, a wholly owned subsidiary company.31 Aug 2026 · Company Update / General
Please find attached intimation regarding completion of term of Independent Director30 Aug 2026 · Company Update / Change in Management
Please find attached outcome of the Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limited, a wholly ....26 Aug 2026 · Company Update / Restructuring
Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly ....26 Aug 2026 · Others / Outcome without intimation
Please find attached intimation regarding ESG Rating22 Aug 2026 · Company Update / General
Please find attached press release dated August 20, 2026.20 Aug 2026 · Company Update / Press Release / Media Release
Please find attached Newspaper Advertisement of Notice of Postal Ballot19 Aug 2026 · Company Update / Newspaper Publication
Please find attched postal ballot notice18 Aug 2026 · AGM/EGM / Postal Ballot

Corporate actions

Purpose	Ex date	Record date	Payment date
Interim Dividend - Rs. - 1.0000	8 Aug 2025	8 Aug 2025	—

Board meetings

26 Oct 2026 Board Meeting - Financial Results
30 Jul 2026 Board Meeting - Financial Results